Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Johnson & Johnson

Share:
Related JNJ
3 Things The Market Is Focused On This Week
Opioid Addiction: What To Do When A Loved One Is Hooked, According To Science
Johnson & Johnson Delivers Strong Results (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Johnson & Johnson (NYSE: JNJ), and raised its price target from $75.00 to $79.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Johnson & Johnson closed on Tuesday at $72.56.

Latest Ratings for JNJ

DateFirmActionFromTo
Jul 2016Argus ResearchUpgradesHoldBuy
Jul 2016JefferiesMaintainsHold
Jun 2016JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!